There are 2789 resources available
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1199P - Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
952P - Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib
Presenter: Dong-Hoon Lim
Session: ePoster Display
1054P - FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
Presenter: Florentia Dimitriou
Session: ePoster Display
1055P - Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma
Presenter: Eftychia Chatziioannou
Session: ePoster Display
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Presenter: Ivan Marquez-Rodas
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display